List of works - Sarat Chandarlapaty

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer

scientific article published on 10 December 2024

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

scientific article

AKT1 E17K inhibits cancer cell migration by abrogating β-catenin signaling

scientific article published on 10 December 2020

Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ

Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma

scientific article published on 05 October 2020

Ash1, a Daughter Cell-Specific Protein, Is Required for Pseudohyphal Growth of Saccharomyces cerevisiae ⬇️

scientific article published on May 1, 1998

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

scientific article published on 20 April 2020

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.

scientific article published on 09 February 2017

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT

scientific article published on 05 May 2016

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

scientific article published on 01 November 2019

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

scientific article published on 05 December 2019

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

scientific article published on August 2017

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies ⬇️

scientific article published on February 1, 2011

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT

scientific article published on 09 June 2020

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer

scientific article

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.

scientific article

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

scientific article published on 09 October 2018

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma

scientific article

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

scientific article published on 8 May 2018

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas ⬇️

scientific article published on November 13, 2012

Reversible histone glycation is associated with disease-related changes in chromatin architecture

scientific article published on 20 March 2019

Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance

scientific article published on 16 April 2018

TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer

scientific article published on 16 April 2021

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.

scientific article published on 29 November 2018

The genomic landscape of metastatic histologic special types of invasive breast cancer

scientific article published on 14 October 2020

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

scientific article published on 10 August 2019

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions

scientific article published on 10 August 2019

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling ⬇️

scientific article published on June 17, 2011

List of works by Sarat Chandarlapaty

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

AKT1 E17K inhibits cancer cell migration by abrogating β-catenin signaling

Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ

Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma

Ash1, a Daughter Cell-Specific Protein, Is Required for Pseudohyphal Growth of Saccharomyces cerevisiae ⬇️

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies ⬇️

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas ⬇️

Reversible histone glycation is associated with disease-related changes in chromatin architecture

Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance

TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.

The genomic landscape of metastatic histologic special types of invasive breast cancer

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling ⬇️